Skip to main content

USPTO Examination Guidelines for Determining Obviousness Under 35 U.S.C. 103

The guidelines aim to help patent examiners assess whether an invention is non-obvious, which is a key requirement for obtaining a patent.


The determination of obviousness involves a legal analysis of whether the claimed invention, as a whole, would have been obvious to a person having ordinary skill in the art at the time the invention was made, based on the prior art available. The MPEP outlines several steps that examiners should follow:


1. Identify the Prior Art: The examiner must locate and consider the relevant prior art that existed before the filing date of the patent application. Prior art includes patents, published patent applications, scientific publications, and other publicly available materials.


2. Determine the Differences: The examiner needs to identify the differences between the claimed invention and the prior art. These differences are known as the "claimed invention features" and are used as a basis for the obviousness analysis.


3. Establish the Level of Ordinary Skill: Examiners must define the level of ordinary skill in the art at the time of the invention. This is a hypothetical person who possesses the average knowledge and skills of practitioners in the relevant field.


4. Assess the Scope and Content of the Prior Art: The examiner evaluates the relevant prior art to understand the state of the technology and the range of information available to the person of ordinary skill.


5. Determine the Motivation to Combine: The examiner considers whether a person of ordinary skill would have been motivated to combine the elements of the prior art to arrive at the claimed invention. Motivation can be explicit (suggested in the prior art) or implicit (based on common knowledge and design incentives).


6. Evaluate Secondary Considerations: Examiners may consider "secondary considerations" or objective indicia of non-obviousness. These include evidence of commercial success, long-felt but unresolved need, unexpected results, and others.


7. Make a Conclusion: Based on the analysis of the above factors, the examiner determines whether the claimed invention would have been obvious or non-obvious to a person of ordinary skill in the art.


It's important to note that the determination of obviousness is a subjective judgment based on the available evidence, and different examiners may reach different conclusions. Applicants can present arguments and evidence to support the non-obviousness of their invention during the patent prosecution process.

Comments

Popular posts from this blog

Pharma Companies HR contact information

Dear viewers of my blog, I am happy to share the HR contact details of Pharmaceutical companies. Contact Details Of Pharma HRs : Zaydus cadila-Goa gajendravernekar@zayduscadila.com 09623458512/08326615143 Teva-Goa Maryann.Braganza@teva.co.in sanjay.pandit@teva.co.in 0832 6685538 Glenmark-Goa Vittal hebbalkar hr executivr - 9923476869 anupbannatti@glenmark-generics.com 09604151586 Watson-Goa Jyosna.bagule@watsonpharm.co.in runa.divkar@watsonpharm.co.in goa@watsonpharm.co.in 0832 6690666/777 Unichem Labs-Goa abhiram.panshikar@unichemlabs.com R&D  suraj.jadhav@unichemlabs.com vikas.parkar@unichemlabs.com Indico-Goa goahplc@Indoco.com varun.keny@indoco.com anand.ingole@Indoco.com 0832 6624109 Encube-Goa hr@encubeethicals.com nidhi.b@encubeethicals.com 8322392223 Torrent pharma-Ahmdabad mayurdesai@torrentpharma.com 9879603921/22/23/24 Emcure-pune RPKulkarni@emcure.co.in           Kishor.Mule@emcur...

Corona virus (Covid-19)

The only way one can combat with Covid-19 is by building one’s immunity & staying healthy by proper hygiene Best medicines for immunity development could be multivitamin pills with zinc,and best foods could be #freshfruits #vegetables. #Mangoes #lemon #oranges are could be the best.

Biogen to seek approval for high-dose version of Spinal Muscular Atrophy stalwart Spinraza (Nusinersen) after trial win

Biogen, which was first to score an endorsement in Spinal Muscular Atrophy (SMA) in 2016, is endeavoring to address it with a higher portion variant of Spinraza #(Nusinersen). On Wednesday, the organization uncovered that a part of its stage 2/3 Commit concentrate on met its essential endpoint, as a higher portion of Spinraza worked on the engine capability of treatment-innocent newborn children with SMA. The review contrasted the high-portion routine with a coordinated, untreated hoax control bunch from the stage 3 Charm study, which empowered Spinraza's unique endorsement. In the Commit preliminary accomplice, 75 patients were randomized 2:1 to get the higher-portion routine or the FDA-endorsed dose of 12 mg, which incorporates four beginning medicines, trailed by support dosages like clockwork. While the high-portion form of Spinraza met the preliminary's endpoint contrasted with joke, the outcomes too "moved in favor" of the investigational routine contrasted with...